Management Controls, Inc. Launches Transparent Lump Sum: A Game-Changer for Contractor Cost Control
Article content
For the first time ever, asset owners can track and manage both Time and Material (T&M) and Lump Sum contractor work in one digital platform—bringing total visibility, accountability, and cost control to every project.
Article content
Article content
HOUSTON — Management Controls, Inc. (MCi), the leader in contractor data and spend management solutions, today announced the launch of Transparent Lump Sum™ (patent pending)—a groundbreaking capability within its myTrack platform that redefines how asset-intensive industries oversee and manage fixed-price contractor work.
Article content
For decades, lump sum contracts have been considered a 'set-it-and-forget-it' model—appealing for their simplicity, but often hindered by a lack of visibility, double billing across contract types, poor performance accountability, and limited oversight of workforce safety and fatigue. With Transparent Lump Sum, MCi eliminates the black box.
Article content
'This is more than a feature—it's a strategic leap,' said Ken Naughton, President of MCi. 'Transparent Lump Sum empowers owners to track progress, validate performance, and manage risk on fixed-price work the same way they do on Time & Materials. No other platform offers this level of unified contractor oversight. MCi has been the undisputed leader in T&M contractor management for decades; now, we have a true game-changer for lump sum to match.'
Article content
With Transparent Lump Sum, clients can now:
Article content
See what risk premium their vendors are charging on Lump Sum work. Industry standards suggest 10-20% risk premium; however, many heavy asset owners are paying 80-100%+ risk premiums but didn't have visibility to prove it—until now.
Compare cost performance between Lump Sum and T&M on the same job to determine which contracting strategy would have delivered better value, empowering data-driven contract strategies for future optimization.
Track and manage Lump Sum and T&M contracts in a centralized platform, thus eliminating double billing through 100% labor, equipment, and material allocation across all contract types.
Validate and track lump sum change orders in real time to ensure additional scope is justified and prevent inflated charges.
Monitor how Lump Sum work is progressing in real time—across labor, equipment, materials, cost, and scope.
Validate milestone payments with attached documentation and earned hour visibility.
Article content
One Platform. All Contractor Spend. Full Visibility.
Article content
myTrack provides complete visibility into both Lump Sum and T&M projects in a single, centralized platform. This breakthrough enables every stakeholder— procurement, operations, finance, and contractors to align on one accurate data source, improving collaboration, eliminating surprises, and driving smarter decisions.
Article content
'Contractor oversight shouldn't depend on the commercial model,' said Ken Naughton. 'Our customers told us they needed transparency, even under fixed-price work. Now with Transparent Lump Sum, our clients gain cost certainty, contract compliance, and complete visibility across all contractor spend—regardless of how they choose to pay their contractors.'
Article content
Transparent Lump Sum is already being adopted by industry leaders in oil & gas, chemicals, power generation, mining, metals, and manufacturing. With this launch, MCi further cements its role as the innovation leader in contractor management. Learn more about Transparent Lump Sum at https://www.managementcontrols.com
Article content
Management Controls, Inc. (MCi) empowers companies to maximize visibility, control, and productivity across their contractor workforce and spend. MCi's myTrack platform delivers automated contract compliance and a unified, real-time view of labor, equipment, and materials costs—enabling smarter, safer execution of maintenance, turnarounds, capital projects, and daily operations. With the addition of MCi's Insights-as-a-Service and managed services, organizations can tap into more than 35 years of expertise to drive even greater value from myTrack and unlock new opportunities to boost site performance and efficiency.
Article content
Article content
Article content
Article content
Contacts
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
2 hours ago
- Cision Canada
Oncolytics Biotech® Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy
SAN DIEGO and CALGARY, Alberta, June 30, 2025 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced the appointment of Andrew Aromando as Chief Business Officer. Mr. Aromando most recently served as Chief Operating Officer at Ambrx Biopharma, where his contributions were instrumental in the $2 billion acquisition of the San Diego-based biotech by Johnson & Johnson. In his role at Oncolytics, Mr. Aromando will be responsible for leading global business development. He will also be directly involved with developing corporate, clinical and regulatory strategies. Among his key priorities will be optimizing the value of the Company's expansive suite of promising clinical data for pelareorep in multiple tumor types, including pancreatic, breast, and anal cancers. "Andrew's experience will be invaluable as we pursue aggressive clinical and business development strategies to maximize the value of pelareorep on an accelerated timeline," said Jared Kelly, Chief Executive Officer of Oncolytics. "He is a proven industry leader with a successful track record of navigating complex transactions and partnerships and an outstanding addition to our executive team." Mr. Aromando added, "I'm thrilled to join Oncolytics at such a pivotal moment in its evolution. With promising data in difficult-to-treat cancers and a compelling body of clinical evidence in over 1,100 patients, I believe the Company is uniquely positioned to deliver meaningful value to patients and other stakeholders in the near term." Mr. Aromando has over 30 years of experience in the life sciences industry. He has served more than 20 years in C-level positions at leading oncology-focused biopharma companies and global service providers. His senior executive roles at these companies were centered on strategic planning, corporate development, portfolio optimization, and product commercialization. He earned his BA from The College of New Jersey and MA from Rutgers University. As a material inducement to Mr. Aromando's appointment as Chief Business Officer, and in accordance with NASDAQ Listing Rule 5635(c)(4), Mr. Aromando has been awarded an initial stock option grant exercisable for 750,000 shares with an exercise price of CAD$0.93, vesting equally over three years with a term of 5 years from the date of grant. The Company also granted Mr. Aromando 500,000 restricted stock units, which vest upon the Company entering into a definitive agreement for certain transactions providing for the acquisition of the Company or the exclusive license of pelareorep. About Oncolytics Biotech Inc. Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized Phase 2 studies in metastatic breast cancer and Phase 1 and 2 studies in pancreatic cancer. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers. Pelareorep has demonstrated synergies with multiple approved oncology treatments. Oncolytics is currently conducting and planning combination clinical trials with pelareorep in solid malignancies as it advances towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA. For more about Oncolytics, please visit: or follow the company on social media on LinkedIn and on X @ oncolytics. This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as "forward-looking statements"). Forward-looking statements contained in this press release include statements regarding Oncolytics' belief as to the potential, mechanism of action and benefits of pelareorep as a cancer therapeutic; our plans, objectives and strategies; our focus on advancing pelareorep into registration enabling studies; and other statements related to anticipated developments in Oncolytics' business and technologies. In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. Such forward-looking statements involve known and unknown risks and uncertainties, which could cause Oncolytics' actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, Oncolytics' ability to successfully commercialize pelareorep, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. We may incur expenses or delays relating to events outside of our control, which could have a material adverse impact on our business, operating results and financial condition. Investors should consult Oncolytics' quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake any obligation to update these forward-looking statements, except as required by applicable laws. Company Contact Jon Patton Director of IR & Communication [email protected] Investor Relations for Oncolytics Mike Moyer LifeSci Advisors +1-617-308-4306 [email protected] Media Contact for Oncolytics Owen Blaschak LifeSci Communications [email protected] SOURCE Oncolytics Biotech® Inc.
Cision Canada
5 hours ago
- Cision Canada
Hisense Showcases AI Technology Strength with "AI YOUR LIFE" Message at FIFA Club World Cup 2025™
QINGDAO, China, June 30, 2025 /CNW/ -- Hisense, a leading brand in global consumer electronics and home appliances, is showcasing its AI leadership at the FIFA Club World Cup 2025™ with the bold pitch-side message "AI YOUR LIFE," reflecting the brand's vision of human-centric innovation through intelligent technology. As one of the earliest consumer tech brands to explore AI, Hisense is integrating intelligent features across its product portfolio. Today, at the core of Hisense's intelligent ecosystem is the Hi-View AI Engine X—its most powerful AI processor yet. Powered by deep neural networks, it learns and adapts like a human brain, optimizing picture and sound across all content, from fast-paced sports to cinematic films and immersive gaming. Driving the next generation of ULED AI TVs, Hi-View AI Engine X powers four key pillars: AI Picture for lifelike contrast, color, and motion; AI Sound for adaptive clarity and immersive acoustics; AI Scenario for automatic mode switching; and AI Energy for top performance with greater efficiency. Together, they create a more immersive, intelligent way to enjoy every match, goal, and moment on screen. Beyond the screen, Hisense expands smart connectivity in the home through ConnectLife. From AI-guided cooking to personalized laundry care, users enjoy seamless, scenario-based intelligence. The PureFlat Smart Series refrigerator, with its 21-inch screen, serves as a convenient hub to manage appliances with ease. For Hisense, whether it's screen or appliance, the essence is home — and the essence of home is love. Now enhanced by AI, that belief evolves—technology becomes more intuitive, responsive, and emotional. As global audiences celebrate football's finest moments, Hisense invites everyone to "Own the Moment" with intelligent products that understand, adapt, and inspire. About Hisense Hisense, founded in 1969, is a globally recognized leader in home appliances and consumer electronics with operations in over 160 countries, specializing in delivering high-quality multimedia products, home appliances, and intelligent IT solutions. According to Omdia, Hisense ranks No. 2 worldwide in total TV volume shipments (2022-2024) and No. 1 globally in the 100-inch and over TV segment (2023- Q12025). As the first official partner of the FIFA Club World Cup 2025™, Hisense is committed to global sports partnerships as a way to connect with audiences worldwide.
Cision Canada
5 hours ago
- Cision Canada
Piramal Pharma Solutions Breaks Ground on $90M Expansion Plan
Piramal Pharma Solutions is investing $90M to expand two of its U.S. facilities, adding commercial-scale manufacturing capabilities and significantly enhancing the capacity and efficiency of each site. Both facilities undergoing expansions are essential components of Piramal Pharma's integrated antibody-drug conjugate (ADC) offering, ADCelerate™, reflecting the company's commitment to delivering innovative solutions that align with patient needs. Piramal Pharma celebrated the groundbreaking of the expansion of its sterile injectables development and manufacturing facility on June 25, 2025. MUMBAI, India, June 30, 2025 /CNW/ -- Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), recently announced a $90M investment plan to expand two of its U.S. facilities, which are critical to its integrated offering. This ambitious investment underscores the company's commitment to industry leadership through continuous growth and innovation. The two sites involved in the expansion are: Riverview, Michigan: The Riverview site provides comprehensive drug substance development and manufacturing services, including specialized solutions for high potency APIs (HPAPIs). This facility is a vital element of ADCelerate™, supplying the payload-linkers essential to the overall safety, stability, and efficacy of ADC therapies. The expansion will add a commercial-scale suite specifically designed for the development and manufacturing of payload-linkers, which is expected to be operational by the end of 2025. Lexington, Kentucky: The Lexington site is Piramal Pharma's dedicated fill/finish facility, specializing in sterile compounding, liquid filling, and lyophilization for sterile injectable drug products. As a critical component of Piramal Pharma's integration, the site provides fill/finish services for all integrated programs, including ADCelerate™ projects. The expansion will add commercial-scale sterile injectable manufacturing capabilities with 24,000 additional square feet of manufacturing space, a new laboratory, and state-of-the-art machinery, including a new filling line, two commercial-size lyophilizers, a specialized capping machine, and an external vial washer. The expansion is expected to be completed by late 2027. Piramal Pharma recently broke ground on the expansion plan for its Lexington, Kentucky facility. To celebrate this important milestone and the future growth it signifies for the company, Piramal Pharma hosted a groundbreaking ceremony at the facility on June 25, 2025. This investment comes at a pivotal moment for the sterile injectables market, which is experiencing significant growth driven by increased medical necessity, broader regulatory approvals, and sizable advancements in scientific research and development. Additionally, the streamlined delivery systems associated with sterile injectables contribute to their efficacy and safety, making these solutions increasingly popular among both healthcare providers and patients. Similarly, ADC therapies are gaining substantial traction, fueled by ongoing innovation, wider regulatory acceptance, and robust evidence demonstrating their effectiveness. The growing prevalence of ADCs underscores the pressing need for expanded manufacturing and development capabilities to meet the evolving landscape of patient care. This investment positions Piramal Pharma to capitalize on these trends, ensuring the company can meet the rising demand for both sterile injectables and ADC therapies while enhancing its competitive edge in the market. Upon completion of the expansion in late 2027, the Lexington site will more than double its manufacturing capacity, increasing from 104 product batches per year (at peak utilization) to over 240 annual batches. "We prioritize patient, consumer, and customer centricity in all our operations, engaging with the populations we serve to better understand, anticipate, and address their needs. Our research has revealed that the sterile injectables market is projected to exceed $20B by 2028, underscoring the urgent need for us to enhance our offerings in this segment. We are confident that this strategic $90M investment will empower us to meet the demands of this market, reinforcing our position as a trusted global partner in biologic manufacturing. By enhancing the services we provide to our partners, we can reduce the burden of disease for more patients around the globe," said Nandini Piramal, Chairperson, Piramal Pharma. "As the market adjusts and preferences shift, we are committed to adapting to meet its current requirements," said Peter DeYoung, Chief Executive Officer, Piramal Global Pharma. "ADCs are rapidly emerging as one of the most effective classes of precision immunotherapy targeting certain cancers and tumors. As this class of drugs becomes more prevalent, we will adapt our services to accommodate this growing demand. By investing in the Lexington and Riverview facilities, we will enhance our integrated ADC offering, ADCelerate™, and increase our capacity to bring high-quality, innovative treatments to our clients and their patients worldwide." The Lexington facility expansion also represents an investment in the local community, creating 40 new full-time jobs that will enhance the local economy and strengthen Piramal Pharma's workforce. Piramal Pharma will continue to work alongside local partners, leveraging the region's strengths to remain at the forefront of innovation. Additionally, this investment aligns with the growing trend toward U.S. onshore manufacturing, reinforcing the company's dedication to domestic production in the U.S. and supply chain resilience. At the groundbreaking ceremony, Lexington Mayor Linda Gorton expressed her excitement about the project and the promising opportunities it presents for the city, stating, "Piramal's decision to expand its facility here in Lexington sends a message around the world that Lexington is a great place to do business. Lexington is home to one of the nation's best pharmacy programs – the University of Kentucky College of Pharmacy – and we are well on our way to becoming a leader in the pharmaceutical industry, as well." Others echoed Mayor Gorton's sentiment with equal enthusiasm, including Jim Stephanou, CEO of IPS-Integrated Project Services, who said, "IPS is a proud supporter of Piramal's growth over the past five years, providing fit-for-purpose solutions on transformative projects across India, the UK, Canada, and the U.S. Our longstanding relationship is built on trust and a relentless commitment to technical excellence. Nothing is more rewarding than seeing shovels in the ground, especially here in Lexington. This groundbreaking highlights our deep expertise in Aseptic Fill/Finish facilities, and our passion to help Piramal bring this advanced manufacturing facility to life to deliver critical therapies to patients around the world." Commerce Lexington President and CEO, Bob Quick, said, "We are proud to celebrate this milestone moment with Piramal and excited for its continued growth and success. Biotech is a key strategic target for Greater Lexington economic development professionals, and this expansion will further strengthen the region as a hub for biotech and life sciences. Piramal's investment highlights the advantages of the area as an exceptional place where innovative companies come to grow and thrive." Piramal Pharma Solutions' $90M investment in its U.S. facilities represents a significant advancement in its manufacturing capabilities and underscores its ongoing commitment to patient-centric care. This strategic move will enable Piramal Pharma to meet the evolving needs of the healthcare landscape, positioning the company at the forefront of the rapidly growing sterile injectables and ADC markets and ensuring a brighter future for patients and communities alike. About Piramal Pharma Solutions Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organization (CDMO) offering end-to-end development and manufacturing solutions across the drug life cycle. We serve our customers through a globally integrated network of facilities in North America, Europe, and Asia. This enables us to offer a comprehensive range of services including drug discovery solutions, process and pharmaceutical development services, clinical trial supplies, commercial supply of APIs, and finished dosage forms. We also offer specialized services such as the development and manufacture of highly potent APIs, antibody-drug conjugations, sterile fill/finish, peptide products and services, and potent solid oral drug products. PPS also offers development and manufacturing services for biologics including vaccines and gene therapies, made possible through Piramal Pharma Limited's associate company, Yapan Bio Private Limited. About Piramal Pharma Limited Piramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio of differentiated products and services through its 17* global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the India Consumer Healthcare business, selling over-the-counter consumer and wellness products. In addition, one of PPL's associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics / bio-therapeutics and vaccine segments. * Includes one facility via PPL's minority investment in Yapan Bio.
